JP2013509593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509593A5 JP2013509593A5 JP2012537132A JP2012537132A JP2013509593A5 JP 2013509593 A5 JP2013509593 A5 JP 2013509593A5 JP 2012537132 A JP2012537132 A JP 2012537132A JP 2012537132 A JP2012537132 A JP 2012537132A JP 2013509593 A5 JP2013509593 A5 JP 2013509593A5
- Authority
- JP
- Japan
- Prior art keywords
- ibs
- sample
- level
- subject
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 58
- 239000003550 marker Substances 0.000 claims 30
- 239000000523 sample Substances 0.000 claims 26
- 238000000034 method Methods 0.000 claims 15
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 8
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 claims 6
- 108010051335 Lipocalin-2 Proteins 0.000 claims 6
- 102000013519 Lipocalin-2 Human genes 0.000 claims 6
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 6
- 108010062431 Monoamine oxidase Proteins 0.000 claims 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 6
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical group OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 229940076279 serotonin Drugs 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 4
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 4
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 4
- 102000001400 Tryptase Human genes 0.000 claims 4
- 108060005989 Tryptase Proteins 0.000 claims 4
- 239000000090 biomarker Substances 0.000 claims 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 4
- 229960001340 histamine Drugs 0.000 claims 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 3
- -1 5-HT glucuronide Chemical class 0.000 claims 3
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 claims 3
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 claims 3
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 claims 3
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 102400000739 Corticotropin Human genes 0.000 claims 3
- 101800000414 Corticotropin Proteins 0.000 claims 3
- 102100032165 Corticotropin-releasing factor-binding protein Human genes 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 3
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 102400001357 Motilin Human genes 0.000 claims 3
- 101800002372 Motilin Proteins 0.000 claims 3
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 claims 3
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 3
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 3
- 101800000399 Neurokinin A Proteins 0.000 claims 3
- 102400000097 Neurokinin A Human genes 0.000 claims 3
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 claims 3
- 102000046798 Neurokinin B Human genes 0.000 claims 3
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 claims 3
- 101800002813 Neurokinin-B Proteins 0.000 claims 3
- 102000004338 Transferrin Human genes 0.000 claims 3
- 108090000901 Transferrin Proteins 0.000 claims 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 3
- 102100040198 UDP-glucuronosyltransferase 1-6 Human genes 0.000 claims 3
- 101710008381 UGT1A6 Proteins 0.000 claims 3
- 108010059705 Urocortins Proteins 0.000 claims 3
- 102000005630 Urocortins Human genes 0.000 claims 3
- JFWYSGGSCOOBGK-UHFFFAOYSA-N [3-(2-azaniumylethyl)-1h-indol-5-yl] sulfate Chemical compound C1=C(OS(O)(=O)=O)C=C2C(CCN)=CNC2=C1 JFWYSGGSCOOBGK-UHFFFAOYSA-N 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 108060000200 adenylate cyclase Proteins 0.000 claims 3
- 102000030621 adenylate cyclase Human genes 0.000 claims 3
- 238000004422 calculation algorithm Methods 0.000 claims 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 3
- 229960000258 corticotropin Drugs 0.000 claims 3
- 108010083720 corticotropin releasing factor-binding protein Proteins 0.000 claims 3
- 230000002950 deficient Effects 0.000 claims 3
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 3
- 229930182480 glucuronide Natural products 0.000 claims 3
- 229960000890 hydrocortisone Drugs 0.000 claims 3
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims 3
- 229940053128 nerve growth factor Drugs 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- 230000001817 pituitary effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000000697 serotonin reuptake Effects 0.000 claims 3
- 239000012581 transferrin Substances 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 239000000777 urocortin Substances 0.000 claims 3
- 206010000060 Abdominal distension Diseases 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 102000013382 Gelatinases Human genes 0.000 claims 2
- 108010026132 Gelatinases Proteins 0.000 claims 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims 2
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 claims 2
- 102000019298 Lipocalin Human genes 0.000 claims 2
- 108050006654 Lipocalin Proteins 0.000 claims 2
- 238000012896 Statistical algorithm Methods 0.000 claims 2
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 claims 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 2
- 238000013480 data collection Methods 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- NPILLHMQNMXXTL-UHFFFAOYSA-N 4,4'-dimethylaminorex Chemical compound CC1N=C(N)OC1C1=CC=C(C)C=C1 NPILLHMQNMXXTL-UHFFFAOYSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 claims 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010008469 Chest discomfort Diseases 0.000 claims 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 1
- 206010058672 Negative thoughts Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 claims 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
- 206010000059 abdominal discomfort Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000013528 artificial neural network Methods 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000024330 bloating Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 208000024798 heartburn Diseases 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 238000007637 random forest analysis Methods 0.000 claims 1
- 238000003118 sandwich ELISA Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25671709P | 2009-10-30 | 2009-10-30 | |
| US61/256,717 | 2009-10-30 | ||
| US26458809P | 2009-11-25 | 2009-11-25 | |
| US61/264,588 | 2009-11-25 | ||
| US32617610P | 2010-04-20 | 2010-04-20 | |
| US61/326,176 | 2010-04-20 | ||
| PCT/US2010/054810 WO2011053831A1 (en) | 2009-10-30 | 2010-10-29 | Methods for diagnosing irritable bowel syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013509593A JP2013509593A (ja) | 2013-03-14 |
| JP2013509593A5 true JP2013509593A5 (enExample) | 2013-12-05 |
Family
ID=43922588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537132A Withdrawn JP2013509593A (ja) | 2009-10-30 | 2010-10-29 | 過敏性腸症候群の診断方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120315630A1 (enExample) |
| EP (1) | EP2494074A4 (enExample) |
| JP (1) | JP2013509593A (enExample) |
| KR (1) | KR20120101038A (enExample) |
| CN (1) | CN102712956A (enExample) |
| AU (1) | AU2010313292A1 (enExample) |
| BR (1) | BR112012010108A2 (enExample) |
| CA (1) | CA2778539A1 (enExample) |
| IL (1) | IL219317A0 (enExample) |
| MX (1) | MX2012005015A (enExample) |
| PH (1) | PH12012500850A1 (enExample) |
| RU (1) | RU2012122180A (enExample) |
| WO (1) | WO2011053831A1 (enExample) |
| ZA (1) | ZA201203718B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5857503B2 (ja) * | 2010-07-29 | 2016-02-10 | 小野薬品工業株式会社 | ストレス性疾患のバイオマーカー |
| EP2710383B1 (en) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| MX2014013719A (es) * | 2012-05-19 | 2015-02-10 | Falk Pharma Gmbh | Composiciones y metodos para el tratamiento del sindrome del intestino irritable con 5-aminosalicilato. |
| SG11201502641YA (en) * | 2012-10-05 | 2015-05-28 | Nestec Sa | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs |
| WO2014082034A1 (en) * | 2012-11-26 | 2014-05-30 | Lexicon Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome |
| CN103175971B (zh) * | 2013-02-28 | 2016-10-05 | 苏州和锐医药科技有限公司 | 一种IgA抗体检测试剂盒 |
| WO2014144129A2 (en) * | 2013-03-15 | 2014-09-18 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| GB201305708D0 (en) * | 2013-03-28 | 2013-05-15 | Clasado Inc | Novel use |
| BR112015029318A2 (pt) * | 2013-05-24 | 2017-07-25 | Nestec Sa | marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável |
| WO2015100353A1 (en) * | 2013-12-27 | 2015-07-02 | Dignity Health | Diagnosing and treating alzheimer's disease |
| WO2015125818A1 (ja) * | 2014-02-18 | 2015-08-27 | 小野薬品工業株式会社 | 過敏性腸症候群の診断用バイオマーカー |
| WO2016205723A2 (en) | 2015-06-19 | 2016-12-22 | Sera Prognostics, Inc. | Biomarker pairs for predicting preterm birth |
| CN106446599A (zh) * | 2015-08-11 | 2017-02-22 | 中国科学院青岛生物能源与过程研究所 | 一种筛选婴幼儿龋病的口腔致病性生物标记物的方法 |
| CN105687225B (zh) * | 2016-02-26 | 2018-07-06 | 四川好医生攀西药业有限责任公司 | 一种治疗肠易激综合征的药物组合物及其制备方法和应用 |
| GB201605110D0 (en) * | 2016-03-24 | 2016-05-11 | Mologic Ltd | Detecting sepsis |
| US10817778B2 (en) | 2016-06-27 | 2020-10-27 | International Business Machines Corporation | Customized cooking utilizing deep learning neuromorphic computing of hyperspectral input |
| KR20250030022A (ko) | 2016-09-16 | 2025-03-05 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 대사물질 바이오마커 |
| RU2668496C2 (ru) * | 2017-03-16 | 2018-10-01 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ диагностики тяжести течения синдрома раздраженного кишечника |
| CN106990057A (zh) * | 2017-05-05 | 2017-07-28 | 贵州普洛迈德生物工程有限公司 | 一种检测5‑羟吲哚乙酸试剂及制备方法 |
| EP4530633A3 (en) | 2017-08-18 | 2025-10-15 | Sera Prognostics, Inc. | Pregnancy clock proteins for predicting due date and time to birth |
| US11488699B1 (en) | 2018-12-09 | 2022-11-01 | Cerner Innovation, Inc. | Microbiota activity sensor and decision support tool |
| US11842795B1 (en) * | 2018-12-17 | 2023-12-12 | Cerner Innovation, Inc. | Irritable bowel syndrome diagnostic sensor and decision support tool |
| KR102330639B1 (ko) * | 2019-01-18 | 2021-11-24 | 주식회사 천랩 | 과민성대장증후군 특이적 미생물 바이오마커와 이를 이용하여 과민성대장증후군의 위험도를 예측하는 방법 |
| US20220146527A1 (en) * | 2019-09-17 | 2022-05-12 | Chang Gung University | Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms |
| WO2021073742A1 (en) * | 2019-10-17 | 2021-04-22 | University Of Copenhagen | Agonist of tacr2 |
| CN112921100A (zh) * | 2019-12-06 | 2021-06-08 | 宁波海尔施基因科技有限公司 | 一种检测人类压力敏感度基因型的试剂盒和方法 |
| EP3913371A1 (en) * | 2020-05-18 | 2021-11-24 | Neuroimmun GmbH | Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions |
| CN111784683B (zh) * | 2020-07-10 | 2022-05-17 | 天津大学 | 病理切片检测方法及装置、计算机设备及存储介质 |
| CN111905111B (zh) * | 2020-09-16 | 2023-03-31 | 地奥集团成都药业股份有限公司 | 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法 |
| US20220208375A1 (en) * | 2020-12-29 | 2022-06-30 | Kpn Innovations, Llc. | System and method for generating a digestive disease functional program |
| CN115328117B (zh) * | 2022-07-15 | 2023-07-14 | 大理大学 | 基于强化学习的蛋白质动态配体通道最优路径分析方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303617B1 (en) * | 1998-05-04 | 2001-10-16 | Neotherapeutics, Inc. | Serotonin-like 9-substituted hypoxanthine and methods of use |
| AU2001288564A1 (en) * | 2000-09-06 | 2002-03-22 | Glaxo Group Limited | 5-hydroxytryptamine receptor gene polymorphisms and response to treatment |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| EP3309556B1 (en) * | 2009-06-25 | 2020-04-08 | Prometheus Biosciences, Inc. | Methods for diagnosing irritable bowel syndrome |
-
2010
- 2010-10-29 PH PH1/2012/500850A patent/PH12012500850A1/en unknown
- 2010-10-29 WO PCT/US2010/054810 patent/WO2011053831A1/en not_active Ceased
- 2010-10-29 JP JP2012537132A patent/JP2013509593A/ja not_active Withdrawn
- 2010-10-29 KR KR1020127013948A patent/KR20120101038A/ko not_active Withdrawn
- 2010-10-29 BR BR112012010108A patent/BR112012010108A2/pt not_active IP Right Cessation
- 2010-10-29 CA CA2778539A patent/CA2778539A1/en not_active Abandoned
- 2010-10-29 MX MX2012005015A patent/MX2012005015A/es unknown
- 2010-10-29 CN CN2010800605536A patent/CN102712956A/zh active Pending
- 2010-10-29 EP EP10827556.1A patent/EP2494074A4/en not_active Withdrawn
- 2010-10-29 AU AU2010313292A patent/AU2010313292A1/en not_active Abandoned
- 2010-10-29 RU RU2012122180/15A patent/RU2012122180A/ru unknown
-
2012
- 2012-04-06 US US13/441,658 patent/US20120315630A1/en not_active Abandoned
- 2012-04-19 IL IL219317A patent/IL219317A0/en unknown
- 2012-05-22 ZA ZA2012/03718A patent/ZA201203718B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509593A5 (enExample) | ||
| JP2012531593A5 (enExample) | ||
| Schwarz et al. | Sick euthyroid syndrome on presentation of patients with COVID-19: a potential marker for disease severity | |
| Perez-Garcia et al. | Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study | |
| JP2019194600A (ja) | 過敏性腸症候群を診断するための経路特異的マーカー | |
| RU2012122180A (ru) | Способы диагностики синдрома раздраженного кишечника | |
| Fiore et al. | Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet | |
| Mansori et al. | A systematic review and meta-analysis of the prevalence of Helicobacter pylori in patients with diabetes | |
| JP6707181B2 (ja) | 早産のリスクがある妊娠女性を同定するためのキットまたはパッケージ、および、当該キットまたはパッケージの使用 | |
| Chawes et al. | Neonates with reduced neonatal lung function have systemic low-grade inflammation | |
| WO2016059636A1 (en) | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof | |
| Zhang et al. | B cell-activating factor as a new potential marker in inflammatory bowel disease | |
| Sabanoglu et al. | Long-term predictive value of cardiac biomarkers in patients with COVID-19 infection. | |
| Riechmann et al. | Rational application of the new European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 2020 criteria for the diagnosis of coeliac disease | |
| CN105849566A (zh) | 肾脏疾病生物标志物 | |
| Beydoğan et al. | The relationship between CRP at admission and thorax CT findings in patients diagnosed with COVID‐19 | |
| Boga et al. | The effect of sarcopenia and serum myokines on prognosis and survival in cirrhotic patients: a multicenter cross-sectional study | |
| US10983133B2 (en) | Diagnosis and treatment of Kawasaki disease | |
| Mulalin et al. | Levels of anti-topoisomerase I antibody correlated with short onset of cardiopulmonary involvement in Thai systemic sclerosis patients | |
| Bomze et al. | Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. | |
| Wilkinson et al. | Diagnostic accuracy of a ‘sarcopenia index’based on serum biomarkers creatinine and cystatin C in 458,702 UK biobank participants | |
| Hanafy et al. | A simple noninvasive score predicts disease activity and deep remission in ulcerative colitis | |
| Sanders et al. | Case-finding for adult celiac disease in patients with reduced bone mineral density | |
| Komiya et al. | Diagnostic utility of C-reactive protein combined with brain natriuretic peptide in acute pulmonary edema: a cross sectional study | |
| Sattgast et al. | Nutritional intake and bone health among adults with probable undiagnosed, untreated celiac disease: What we eat in America and NHANES 2009–2014 |